

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1118720/publications.pdf>

Version: 2024-02-01

42  
papers

2,381  
citations

218592

26  
h-index

265120

42  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1499  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). <i>Epilepsy Research</i> , 2013, 103, 2-30.	0.8	201
2	Cytochrome P450 Isozymes and Antiepileptic Drug Interactions. <i>Epilepsia</i> , 1995, 36, S8-13.	2.6	168
3	Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). <i>Epilepsy Research</i> , 2015, 111, 85-141.	0.8	161
4	Valproic acid dosage and plasma protein binding and clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 486-492.	2.3	150
5	Bidirectional interaction of valproate and lamotrigine in healthy subjects*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 145-156.	2.3	119
6	Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 48, 225-235.	2.3	113
7	Time-course of interaction between carbamazepine and clonazepam in normal man. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 316-323.	2.3	108
8	Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly adults. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 697-700.	2.3	108
9	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. <i>Epilepsia</i> , 2018, 59, 1811-1841.	2.6	108
10	Stiripentol kinetics in epilepsy: Nonlinearity and interactions. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 661-669.	2.3	95
11	Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (<sc>EILAT XIII</sc>). <i>Epilepsia</i> , 2017, 58, 181-221.	2.6	92
12	Rationale for Monitoring Free Drug Levels. <i>Clinical Pharmacokinetics</i> , 1984, 9, 1-9.	1.6	91
13	Phenobarbital-valproic acid interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 515-521.	2.3	68
14	Valproic Acid: Reversibly Acting Drug?. <i>Epilepsia</i> , 1976, 17, 477-479.	2.6	67
15	Stiripentol in Atypical Absence Seizures in Children: An Open Trial. <i>Epilepsia</i> , 1993, 34, 305-311.	2.6	62
16	Pharmacokinetics of Stiripentol in Normal Man: Evidence of Nonlinearity. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 523-533.	1.0	51
17	Effects of carbamazepine on valproic acid kinetics in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 629-634.	2.3	50
18	Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2020, 61, 2365-2385.	2.6	45

#	ARTICLE	IF	CITATIONS
19	Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. <i>Epilepsia</i> , 2018, 59, 1842-1866.	2.6	44
20	Effects of Pregnancy on Antiepileptic Drug Utilization. <i>Epilepsia</i> , 1985, 26, S52-7.	2.6	43
21	Effects of Valproate and Citrulline on Ammonium-Induced Encephalopathy. <i>Epilepsia</i> , 1994, 35, 164-171.	2.6	37
22	Kinetics of a carbamazepine-ethosuximide interaction. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 646-651.	2.3	36
23	Pharmacokinetic Profile of a New Anticonvulsant, Stiripentol, in the Rhesus Monkey. <i>Epilepsia</i> , 1983, 24, 692-702.	2.6	36
24	Efficacy Testing of Valproic Acid Compared to Ethosuximide in Monkey Model: II. Seizure, EEG, and Diurnal Variations. <i>Epilepsia</i> , 1977, 18, 205-224.	2.6	33
25	Nefopam enantiomers: Preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration. , 2000, 12, 153-159.		29
26	Clorazepate kinetics in treated epileptics. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 22-30.	2.3	26
27	Î²â€Oxidation of Valproic Acid.. <i>Epilepsia</i> , 1989, 30, 782-789.	2.6	21
28	Pharmacokinetic Evaluation of Anticonvulsants Prior to Efficacy Testing Exemplified by Carbamazepine in Epileptic Monkey Model. <i>Epilepsia</i> , 1974, 15, 351-359.	2.6	19
29	Phenytoinâ€Valproic Acid Interaction in Rhesus Monkey. <i>Epilepsia</i> , 1981, 22, 19-25.	2.6	17
30	Experimental Anticonvulsant Cinromide in Monkey Model: Preliminary Efficacy. <i>Epilepsia</i> , 1979, 20, 339-350.	2.6	15
31	Short Communication Carbamazepine Revisited in a Monkey Model. <i>Epilepsia</i> , 1979, 20, 169-173.	2.6	14
32	Pharmacokinetic Properties of Ethosuximide in Monkeys. I. Singleâ€Dose Intravenous and Oral Administration. <i>Epilepsia</i> , 1975, 16, 705-716.	2.6	13
33	Clonazepam in a Focalâ€Motor Monkey Model: Efficacy, Tolerance, Toxicity, Withdrawal, and Management. <i>Epilepsia</i> , 1979, 20, 683-695.	2.6	12
34	Î²â€Oxidation of Valproate. <i>Epilepsia</i> , 1989, 30, 790-796.	2.6	12
35	Efficacy Testing of Valproic Acid Compared to Ethosuximide in Monkey Model: I. Dosage Regimen Design in the Presence of Diurnal Oscillations. <i>Epilepsia</i> , 1977, 18, 191-203.	2.6	11
36	Short Communication Cinromide's Metabolite in Monkey Model: Gastric Administration and Seizure Control. <i>Epilepsia</i> , 1980, 21, 177-182.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Systemic Interaction Between Valproic Acid and Free Fatty Acids in Rhesus Monkeys. <i>Epilepsia</i> , 1982, 23, 649-656.	2.6	9
38	Interactions of Phenytoin and Phenobarbital in Terms of Order and Temporal Spacing of Administration in Monkeys. <i>Epilepsia</i> , 1976, 17, 481-485.	2.6	8
39	Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1986, 7, 11-19.	1.1	5
40	A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). <i>Epilepsy Research</i> , 2019, 153, 66-67.	0.8	3
41	Disposition of Progabide and Valproic Acid Following Intraperitoneal Administration in Rhesus Monkey. <i>Epilepsia</i> , 1984, 25, 578-585.	2.6	2
42	Recent Case Studies of Clinically Significant Drug-Drug Interactions and the Limits of In Vitro Prediction Methodology. , 0, , 195-200.		0